EGFR and non-small cell lung carcinoma: In addition, in NSCLC, when EGFR is altered, phosphorylated STAT3 is overexpressed, so the JAK/STAT3 signaling axis triggers survival, proliferation and resistance to the EGFR inhibitors [14].